← Leaderboards
Pingping Hou
Rutgers Biomedical And Health Sciences
$2,730,524
Attributed
$2,730,524
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.2M · FY2022–25$2M$1.5M$1M$500K$0
'22
'23
'24
'25
Funding mix
By agency
NIH$2,730,524 · 3
By mechanism
R01$1,725,994 · 1
K22$600,843 · 1
R21$403,687 · 1
Top collaborators
No co-investigators on record.
Most similar at Rutgers Biomedical And Health Sciences
Same institution · by research overlap
- Amariliz Rivera$7,526,834
- Shridar Ganesan$8,375,704
- Wei-Xing Zong$16,617,751
- Chaoyang Xue$11,441,263
- Sergei V Kotenko$7,576,497
Others in their field
Other Rising Stars on “Tumor Growth”
- Gary G Schwartz · University Of North Dakota$4,000,000
- David G Brooks · Boston Immune Technologies And Therapeutics, Inc.$3,974,764
- Amy Fowler · University Of Wisconsin-Madison$3,836,115
- Kenneth Schultz · Trethera Corporation$3,602,875
- Shahzad Siddique · Commonspirit Health Research Institute$3,526,795
- Emil Schueler · University Of Tx Md Anderson Can Ctr$3,198,082
Research focus
Tumor GrowthMalignant Neoplasm Of PancreasTumorMouse ModelSignal TransductionDisorder ControlPancreatic Ductal AdenocarcinomaTargeted TreatmentMalignant NeoplasmsCellsImpairmentPancreatic Ductal Adenocarcinoma ModelProgramsResistanceMacrophageInhibitorCytokineKras2 GeneScreeningPathway InteractionsGeneticMutantNeoplasm MetastasisIn Vivo
Grant awards (7)
Develop Conditionally Armored CAR Macrophage Therapy for Pancreatic Cancer$550,769
R01 · FY2025 · CA · contact PI
Develop Conditionally Armored CAR Macrophage Therapy for Pancreatic Cancer$572,707
R01 · FY2024 · CA · contact PI
Develop universal CAR macrophage cell therapy for pancreatic cancer$403,687
R21 · FY2024 · CA · contact PI
Tumor-TAMs crosstalk enables bypass of oncogenic KRAS dependency in pancreatic cancer$200,281
K22 · FY2024 · CA · contact PI
Develop Conditionally Armored CAR Macrophage Therapy for Pancreatic Cancer$602,518
R01 · FY2023 · CA · contact PI
Tumor-TAMs crosstalk enables bypass of oncogenic KRAS dependency in pancreatic cancer$200,281
K22 · FY2023 · CA · contact PI
Tumor-TAMs crosstalk enables bypass of oncogenic KRAS dependency in pancreatic cancer$200,281
K22 · FY2022 · CA · contact PI